Document:

Exhibit 10.6

 

AGREEMENT

 

        This
Agreement ("Agreement") is entered into by and between Sergio Traversa ("Director" or "you") and
Actinium Pharmaceuticals, Inc. (the "Company" or “Actinium”), and confirms the agreement that has been reached
with you in connection with your resignation as a director of the Company (together, the “Parties”).

 

1.    Director
Resignation.    Based on discussions with the board of directors (the “Board”) of the Company
about your intent to focus your attention on matters external to Actinium, you and the Board mutually agree that your resignation
shall be effective as of June 6, 2017 (the "Resignation Date") and as of such date you shall cease to be a member of
the Board of the Company, including any Board committees (as well as of the Board of Directors of any of the Company's subsidiaries).

 

2.    Director Compensation.
In consideration of your execution of this Agreement and your compliance with its terms and conditions, the Company agrees to pay
or provide you (subject to the terms and conditions set forth in this Agreement) within five days of the Resignation Date, with
the Company’s standard director compensation and committee fees until December 31, 2017.  

 

3.    Options.    Each
of your outstanding vested options, as well as 69,000 unvested options granted prior to December 31, 2016, to acquire Company common
stock shall also be exercisable until the end of the term of each option grant agreement. 

 

4.    Indemnification.
The agreements entered into by and between the Company and you and the indemnification sections of the other agreements shall remain
in full force and effect and shall not limit any greater rights provided and/or available to you by any Directors and Officers
liability insurance policy, applicable documents or as a matter of law.

 

5.    No
Other Payments or Benefits.    You acknowledge and agree that, subject to Section 2 of this Agreement,
other than the payments and benefits expressly set forth in this Agreement, you have received all compensation to which you are
entitled from the Company, and you are not entitled to any other payments or benefits from the Company. The Company also agrees
to directly pay to counsel of your choosing the legal expenses you incur in connection with this Agreement.

 

6.    Nondisparagement.    
The Parties agree that each Party, will not, with intent to damage, disparage or encourage or induce others to disparage the other
Party, including, as it relates to the Company, the Company’s subsidiaries and affiliates, together with all of their respective
past and present directors and officers and each of their successors and assigns (collectively, the "Company Entities and
Persons"). Nothing in this Agreement is intended to or shall prevent you or the Company from providing, or limiting testimony
in response to a valid subpoena, court order, regulatory request or other judicial, administrative or legal process or otherwise
as required by law. The Parties each agree that each Party will notify the other Party in writing as promptly as practicable after
receiving any request for testimony or information in response to a subpoena, court order, regulatory request or other judicial,
administrative or legal process or otherwise as required by law, regarding the anticipated testimony or information to be provided
and at least ten (10) days prior to providing such testimony or information (or, if such notice is not possible under the
circumstances, with as much prior notice as is possible).

 

7.    Cooperation.    Prior
to and after the Resignation Date, you agree that you will reasonably cooperate with the Company, its subsidiaries and affiliates,
at any level, and any of their officers and directors, shareholders (A) concerning requests for information about the business
of the Company or its subsidiaries or affiliates or your involvement and participation therein, (B) in connection with any
investigation or review by the Company or any federal, state or local regulatory, quasi-regulatory or self-governing authority
(including, without limitation, the Securities and Exchange Commission) as any such investigation or review relates to events or
occurrences that transpired while you were a director of the Company and (C) with respect to transition and succession matters
(although you and the Company agree that any such transition and succession matters shall be concluded by the Resignation Date).
Your reasonable cooperation may include, but not be limited to (taking into account your personal and professional obligations,
including those to any new employer or entity to which you provide services), being available to meet and speak with officers or
employees of the Company and/or the Company's counsel at reasonable times and locations, executing accurate and truthful documents
and taking such other actions as may reasonably be requested by the Company and/or the Company's counsel to effectuate the foregoing.
You shall be entitled to reimbursement, upon receipt by the Company of suitable documentation, for reasonable and necessary travel
and other expenses (including the reasonable attorneys’ fees actually incurred in the event a conflict of interest between
you and the Company necessitates you retaining your own counsel in order to provide the cooperation hereunder) which you may incur
at the specific request of the Company and also any lost compensation due to fulfilling the obligations imposed by the Company
or its representatives in such matters and as approved by the Company in advance and in accordance with its policies and procedures
established from time to time.

 

    	 	1	 

     

    

 

8.   Mutual
Releases. You agree that, in consideration of this Agreement, you hereby waive, release and forever discharge any and all claims
and rights which you ever had, now have or may have against the Company and any of its subsidiaries or affiliated companies, and
their respective successors and assigns, current and former officers, agents, directors, representatives and employees, various
benefits committees, and their respective successors and assigns, heirs, executors and personal and legal representatives (the
“Company Released Parties”), based on any act, event or omission occurring before you execute this Agreement arising
out of, during or relating to your services with the Company or the termination of such services, except as provided below. This
waiver and release includes, but is not limited to, any claims which could be asserted now or in the future, under: common law,
including, but not limited to, breach of express or implied duties, wrongful termination, defamation, or violation of public policy;
any policies, practices, or procedures of the Company; any federal or state statutes or regulations. Notwithstanding the foregoing,
the Parties agree that you are not waiving any claims or rights: (a) that may arise after the date on which you sign this Agreement,
including the right to enforce this Agreement; (b) that cannot be released as a matter of law; (c) to accrued, vested benefits
under any benefit, stock, savings, insurance or pension plan of the Company; and (d) to indemnification, advancement contribution
or defense, which are expressly reserved as set forth in Section 4 hereof.

 

The Company Released Parties hereby waive,
release and forever discharge any and all claims and rights which such party ever had, now has or may have against you, and your
respective successors and assigns, and your respective successors and assigns, heirs, executors and personal and legal representatives,
based on any act, event or omission occurring before you execute this Agreement arising out of, during or relating to your services
with the Company or the termination of such services, except as provided in Section 9 below. This waiver and release includes,
but is not limited to, any claims which could be asserted now or in the future, under: common law, including, but not limited to,
breach of express or implied duties, wrongful termination, defamation, or violation of public policy; any policies, practices,
or procedures of the Company; any federal or state statutes or regulations.

 

9.    Enforcement.
If any provision of this Agreement is held by a court of competent jurisdiction to be illegal, void or unenforceable, such provision
shall have no effect; however, the remaining provisions shall be enforced to the maximum extent possible. Further, if a court should
determine that any portion of this Agreement is overbroad or unreasonable, such provision shall be given effect to the maximum
extent possible by narrowing or enforcing in part that aspect of the provision found overbroad or unreasonable. In addition, you
agree that your willful and knowing failure to return Company property that relates to the maintenance of security of the Company
Entities and Persons shall entitle the Company to injunctive and other equitable relief.

 

10.    Successors.
This Agreement is binding upon, and shall inure to the benefit of, the parties and their respective heirs, executors, administrators,
successors and assigns.

 

11.    Choice of Law.
This Agreement shall be construed and enforced in accordance with the laws of the State of New York without regard to the principles
of conflicts of law.

 

12.    Counterparts.
This Agreement may be executed in one or more counterparts, including emailed or telecopied facsimiles, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument.(signature page follows)

 

    	 	2	 

     

    

 

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date set forth below.

 

	Signature: 	 	Actinium Pharmaceuticals, Inc. 	 	 
	 	 	 	 	 
	 	 	/s/ Sandesh	 	Date: June 6, 2017 
	 	 	Sandesh Seth, Chairman & CEO	 	 
	 	 	 	 	 
	 	 	/s/ Sergio Traversa	 	Date: June 6, 2017 
	 	 	Sergio Traversa	 	 

 

 

3Exhibit
10.7

 

Actinium
Pharmaceuticals, Inc.

Confidential

 

CONSULTING
AGREEMENT

 

This
Consulting Agreement (“Agreement”) is entered into on May 22, 2017 (the “Effective Date”)
by and between Actinium Pharmaceuticals, Inc., a Delaware corporation with a business address at 275 Madison Avenue, 7th
Floor, New York, NY 10016 (the “Company”), and Dragan Cicic (“Consultant”).

 

WHEREAS,
the Company desires that Consultant provide consulting services to assist the Company with the series describe on Schedule
1 (collectively referred to as the “Services”); and

 

WHEREAS,
Consultant has the requisite knowledge and experience to provide the Services;

 

NOW,
THEREFORE, the Company and Consultant agree as follows:

 

1.
Activities. The Services shall be conducted according to the scope set forth herein.

 

2.
Project Materials and Consultant Services.

 

2.1
The Company will from time to time provide Consultant with access to product information and documents, as well as reports
and experimental data and other information, so as to enable Consultant to provide the Services.

 

2.2
Consultant agrees to communicate to the Company, its designees, successors, legal representatives or assigns, any facts or
other information known to Consultant relating to the Services.

 

2.3
Consultant will provide to the Company weekly reports pertaining to the services performed under this Agreement. Consultant
agrees to adhere to professional record keeping standards and such record keeping reports shall belong to the Company.

 

3.
Reasonable Efforts. Consultant agrees to use all reasonable efforts to provide the Services required under this Agreement
within a reasonable time period. Consultant shall perform Services conscientiously and in a professional manner, and devote his/h
best efforts and abilities thereto. Consultant shall observe all policies and procedures of the Company.

 

4.
Compliance with Laws/No Conflicting Agreement. The Services will be provided in accordance with, and Consultant will
comply with, all federal, state, and local laws and regulations applicable to the Services. Consultant represents and warrants
that Consultant is not a party to any existing agreement that would prevent Consultant from entering into and performing its obligations
under this Agreement in accordance with its terms. Consultant shall not enter into any agreement that is in conflict with, or
that would prohibit or impair the performance of, Consultant’s obligations under this Agreement in accordance with its terms.

 

    	Actinium-Consulting Agreement
	Page 1 of 9	 

     

    

 

Actinium
Pharmaceuticals, Inc.

Confidential

 

5.
Payments and Expenses

 

5.1.
Service Fee. In consideration of the Services to be performed under this Agreement, the Company shall provide compensation
to Consultant for his activities hereunder in the amount of (US $70,750) (“Service Fee”).
The Service Fee shall be payable in bi-weekly installments over a period starting on May 22, 2017 and ending on August 21, 2017.

 

5.2.
Expenses. In addition to the Service Fees referenced in paragraph 5.1 above, the Company will reimburse Consultant
for reasonable and customary travel, lodging and out-of-pocket expenses incurred, in each case at the Company’s written
request, in connection with the performance of the Services. The Company will not be liable for payment of any travel, lodging
or out-of-pocket expenses incurred by Consultant without the prior written authorization of the Company.

 

5.3.
Payment Method.

 

The
Service Fee payments shall be tendered in the form of checks payable to Dragan Cicic, and sent to Consultant at the following
address via First Class U.S. mail: 393 17th Street, Apt 1A, Brooklyn, NY 11215

 

6.
Independent Contractor.  Consultant’s relationship to the Company under this Agreement shall be that of an independent
contractor and not an agent, joint venturer, or partner of the Company. Consultant will be responsible for all applicable federal,
state and local withholding taxes and unemployment taxes, as well as social security, state disability insurance, workers’
compensation and all other payroll charges payable to, or on behalf of, Consultant.

 

7.
Debarment and Exclusion.  Consultant represents, warrants and covenants that for the term of this Agreement, Consultant
is not:

 

a)
debarred under Section 306(a) or 306(b) of the United States Federal Food, Drug and Cosmetic Act, as may be amended and supplemented
from time to time (“FDCA”);

 

b)
has not been charged with, or convicted of, any felony or misdemeanor within the ambit of 42 U.S.C. §§ 1320a-7(a), 1320a-7(b)(l)-(3),
and is not proposed for exclusion during the term of this Agreement;

 

c)
is not excluded, suspended or debarred from participation, or otherwise ineligible to participate, in any Federal or State health
care programs (including convicted of a criminal offense that falls within the scope of 42 U.S.C. §1320a-7 but is not yet
excluded, debarred, suspended, or otherwise declared ineligible), or excluded, suspended or debarred from participation, or otherwise
ineligible to participate, in any Federal procurement or non-procurement programs.

 

Notwithstanding
any provision in this Agreement to the contrary, the Company may immediately terminate this Agreement if Consultant violates any
of the provisions of this paragraph 7. Consultant will notify the Company immediately, but in no event later than five (5) business
days, after obtaining knowledge of any such exclusion, debarment, suspension or other ineligibility occurring during the term
of this Agreement, or if any action or investigation is pending.

 

    	Actinium-Consulting Agreement
	Page 2 of 9	 

     

    

 

Actinium
Pharmaceuticals, Inc.

Confidential

 

8.
Effective Date and Term. The term of this Agreement shall begin on the Effective Date and shall continue for three
(3) months thereafter unless earlier terminated pursuant to Section 9 (the period from the Effective Date through and including
the termination date is the “Term”).

 

9.
Termination. Either party may terminate Consultant’s services at any time and for any reason or no reason, upon
5 days written notice. If the Term is less than three (3) months, then the fee set forth in Section 5.1 shall be prorated.

 

10.
The primary contact at the Company for this Agreement is its Executive Chairman or designee.

 

11.
Data and Reporting. All written materials, comments, critiques, conclusions, data, analyses, models, graphs, equations,
statistical methodologies and other relevant information generated or utilized by Consultant during and pursuant to performing
the Services will be promptly and fully disclosed to the Company, and shall be freely usable in all respects by the Company consistent
with good business judgment and in the Company’s sole discretion. Subject to the provisions of Paragraph 12 below, Consultant
shall be free to maintain a single archival copy of all materials generated by Consultant and related to the Services.

 

12.
Confidential Information.

 

12.1.
“Confidential Information” means all information provided by or on behalf of the Company to Consultant or generated
by Consultant during and pursuant to performing the Services hereunder, whether in written or oral form.

 

12.2.
Consultant shall use the Confidential Information solely for the purpose of performing the Services pursuant to this Agreement.
Consultant shall keep all Confidential Information in confidence, and shall not disclose the Confidential Information to anyone.
Consultant shall not disclose any Confidential Information (including through lecture, presentation, manuscript, abstract, poster
or any other publication) without prior written authorization from the Company. This provision shall remain in effect for five
(5) years following the termination of this Agreement.

 

    	Actinium-Consulting Agreement
	Page 3 of 9	 

     

    

 

Actinium
Pharmaceuticals, Inc.

Confidential

 

12.3.
Specifically excepted from the definition of Confidential Information is all information that:

 

a)
is already known by Consultant at the time of disclosure by the Company as demonstrated by prior written records, and that is
not the subject of a separate confidentiality agreement between the Company and Consultant; or

 

b)
is already available or becomes available in print or other tangible form to the public through no fault of the Consultant;

 

c)
is received by the Consultant from a third party who has the right to disclose it, and who did not receive it, directly or indirectly,
from the Company; or

 

d)
is independently developed by Consultant without use of, reference to or reliance on in any manner whatsoever the Confidential
Information or any information that is the subject of a separate confidentiality agreement between the Company and Consultant.

 

12.4.
Consultant agrees not to make copies of any the Company’s disclosures or other Confidential Information other than those
copies required by Consultant to perform the Services pursuant to this Agreement. Upon the Company’s request, Consultant
shall return to the Company all such information, including any copies thereof.

 

12.5.
In the event that any Confidential Information is required to be disclosed pursuant to any judicial or government request,
requirement or order, Consultant shall take reasonable steps to provide the Company with sufficient prior notice in order to allow
the Company to contest such request, requirement or order. In such event, Consultant will cooperate reasonably with the Company,
at the Company’s expense, in seeking confidential treatment of such requested or compelled disclosure.

 

13.
Publication. Consultant shall not use any Confidential Information or the results of the Services for teaching, research,
education, clinical or publication purposes without the prior written consent of the Company.

 

14.
Intellectual Property

 

14.1.
Assignment of Inventions. Consultant shall promptly make full written disclosure to the Company, shall hold in trust
for the sole right and benefit of the Company, and hereby assigns, transfers and conveys to the Company, or its designee, all
of Consultant’s worldwide right, title and interest in and to any and all inventions, original works of authorship, findings,
conclusions, data, discoveries, developments, concepts, improvements, trade secrets, techniques, processes and know-how, whether
or not patentable or registrable under patent, copyright or similar laws, that Consultant may solely or jointly conceive, develop
or reduce to practice, or cause to be conceived, developed or reduced to practice, in the performance of the Services or that
result, to any extent, from use of the Company’s premises or property (collectively, the “Inventions”),
including any and all moral rights and intellectual property rights inherent therein and appurtenant thereto, including, but not
limited to, all patent rights, copyrights, trademarks, know-how and trade secrets and the rights to apply for the same (collectively,
“Intellectual Property Rights”). Consultant further acknowledges and agrees that all original works of authorship
that are made by Consultant (solely or jointly with others) in the performance of the Services (a “Work”) and
that are protectable by copyright are “works made for hire,” as that term is defined in the United States Copyright
Act. However, to the extent that any Work may not, by operation of any applicable law, be a work made for hire, Consultant hereby
assigns, transfers and conveys to the Company all of Consultant’s worldwide right, title and interest in and to such Work,
including all Intellectual Property Rights relating thereto. Consultant will assist the Company, if requested by the Company,
in processing patent applications and assisting with other Intellectual Property matters beyond 12 weeks consulting period at
an hourly rate of $250 paid to Consultant plus all expenses.

 

    	Actinium-Consulting Agreement
	Page 4 of 9	 

     

    

 

Actinium
Pharmaceuticals, Inc.

Confidential

 

14.2
Consultant acknowledges that he is under no obligation, and will be under no obligation, to assign his rights, if any, in
the Intellectual Property to any other party. Consultant has not made any agreements, assignments, covenants or encumbrances inconsistent
with the provisions of this Agreement and will not enter into any such agreements, assignments, covenants or encumbrances during
the Term of this Agreement, unless instructed to do so by the Company, or expressly permitted to do so by the Company.

 

14.3.
Consultant agrees to assist the Company, at the Company’s expense, in preparing or supporting any applications for patent
term extension (both domestic and foreign), and in preparing and prosecuting any and all applications for intellectual property
protection, both domestic and foreign, on any and all Intellectual Property which the Company decides, in its sole discretion,
to protect in accordance with this Paragraph 14.

 

14.4.
Consultant agrees to communicate to the Company, its designees, successors, legal representatives or assigns, any facts or
other information known to Consultant relating to any of said Intellectual Property. Consultant also agrees to testify in any
subsequent legal proceeding, sign any and all lawful papers, execute any and all provisional, parent, divisional, continuing,
reissue and foreign applications, make all rightful oaths and declarations, and generally do everything possible to assist the
Company, its designees, successors, legal representatives or assigns, at the Company’s expense, to obtain, maintain, defend,
extend, and enforce said Intellectual Property in any and all countries worldwide at the Company’s sole discretion.

 

    	Actinium-Consulting Agreement
	Page 5 of 9	 

     

    

 

Actinium
Pharmaceuticals, Inc.

Confidential

 

14.5
Further Assurances. Upon the request and at the expense of the Company, Consultant shall execute and deliver any and
all instruments and documents and take such other acts as may be necessary or desirable to document the assignment and transfer
described in Section 5.1 or to enable the Company to secure its rights in the Inventions, Works and Intellectual Property Rights
relating thereto in any and all jurisdictions, or to apply for, prosecute and enforce Intellectual Property Rights in any and
all jurisdictions with respect to any Inventions or Works, or to obtain any extension, validation, re-issue, continuance or renewal
of any such Intellectual Property Right. Without limiting the foregoing, Consultant shall disclose to the Company all pertinent
information and data with respect thereto and shall execute all applications, specifications, oaths and all other instruments
which the Company deems necessary in order to apply for and obtain such rights and in order to assign and convey to the Company
the sole and exclusive right, title and interest in and to such Inventions, Works and any Intellectual Property Rights relating
thereto. If the Company is unable for any other reason to secure Consultant’s signature to apply for or to pursue any application
for any United States or foreign patent, trademark, copyright or other registration covering Inventions or Works assigned to the
Company hereunder, then Consultant hereby irrevocably designates and appoints the Company and its duly authorized officers and
agents as Consultant’s agent and attorney in fact, to act for and in Consultant’s behalf and stead to execute and
file any such applications and to do all other lawfully permitted acts to further the prosecution and issuance of letters patent
or trademark, copyright or other registrations thereon with the same legal force and effect as if executed by Consultant.

 

15.
The Company agrees that Consultant’s services are provided without representation or warranty pf any kind. The Company
acknowledges that drug development carries inherent risks and that no particular work product or business result is guaranteed
under this Agreement.

 

16.
Use of a Party’s Name. Neither party (Company or Consultant) will, without the prior written consent of the other party,
use in advertising, publicity, or otherwise, the name, trademark, logo, symbol, or other image of the other party or that party’s
employee(s) or agent(s).

 

17.
Adverse Event Reporting. As part of doing business with the Company, Consultant agrees to assist the Company in ensuring
that any Adverse Events (AEs) or Product Complaints (PCs) involving the Company’s products that Consultant becomes aware
of are appropriately reported.

 

    	Actinium-Consulting Agreement
	Page 6 of 9	 

     

    

 

Actinium
Pharmaceuticals, Inc.

Confidential

 

18.
Notice. Any notice or other communication required or permitted under this Agreement shall be in writing and will be
deemed given as of the date it is received by the receiving party. Notice shall be given to the parties at the addresses listed
below:

 

	 	As to Consultant: 	Dragan Cicic

	 	393 17th Street Apt 1A

	 	Brooklyn NY 11215

 

	 	As to the Company: 	Actinium Pharmaceuticals, Inc.

	 	757 Madison Avenue, 7th Floor

	 	New York, NY 10016

	 	Attn: Executive Chairman

 

19.
Modification. Any alteration, modification, or amendment to this Agreement must be in writing and signed by both parties.

 

20.
Assignment. Consultant may not assign any of its rights or obligations under this Agreement without the prior written
consent of the Company. The Company may freely assign any of its rights and obligations under this Agreement to any of its Associated
Companies.1 No assignment shall relieve either party of the performance of any accrued obligation that such party may
have under this Agreement.

 

21.
Force Majeure. Neither party shall be liable for any delay or failure to perform as required by this Agreement to
the extent that such delay or failure to perform is caused by circumstances reasonably beyond either party’s control, including
without limitation labor disputes, accidents, any law, order or requirement of any governmental agency or authority, civil disorders
or commotions, acts of aggression, fire or other casualty, strikes, acts of God, explosions, or material shortages. Performance
time shall be considered extended for a period of time equivalent to the time lost because of any such delay or failure to perform;
however, in any event, this extension of time shall not exceed fifteen (15) days unless the parties agree otherwise in writing.

 

22.
Applicable Law. This Agreement will in all respects be governed by, and interpreted, construed and enforced in accordance
with, the laws of the State of New York. The parties further agree that any action or proceeding arising out of or in connection
with this Agreement will be venued in a federal or state court of appropriate venue and subject matter jurisdiction located in
the State of New York. Each party hereto irrevocably consents to the personal jurisdiction of the courts in the State of New York.

 

23.
IRS EIN and W-9. Consultant will complete and submit to the Company a US Internal Revenue W-9 Form. Consultant acknowledges
that the Company will rely upon the foregoing certification in filing certain documents and instruments required by law in connection
with this Agreement, including, without limitation, Form 1099 under the Internal Revenue Code of 1986, as amended (or any successor
form).

 

24.
Waiver. No waiver of any term, provision or condition of this Agreement, whether by conduct or otherwise in any one
or more instances, shall be deemed to be, or be construed as, a further or continuing waiver of any such term, provision, or condition,
or of any other term, provision or condition of this Agreement.

 

25.
Entire Agreement. This Agreement, together with all Exhibits, constitutes the entire agreement between the parties
with respect to the subject matter contained herein. This Agreement supersedes all prior understandings and agreements between
the parties with respect to the subject matter contained herein. For the avoidance of doubt, the separation and Settlement Agreement
dated May 12, 2017 remains in full force and effect. This Agreement and the rights and obligations set forth herein may not be
modified, amended or waived, whether in whole or in part, except by a writing signed by both parties.

 

 

1
As used in this Agreement, “Associated Company(ies)” shall mean any person, firm, trust, partnership, corporation,
company or other entity or combination thereof, which directly or indirectly (a) controls a party (b) is controlled by a party
or (c) is under common control with a party. The terms “control” and “controlled” meaning ownership of fifty
percent (50%) or more, including ownership by trusts with substantially the same beneficial interests, of the voting and equity
rights of such person, firm, trust, corporation or other entity or combination thereof or the power to direct the management of
such person, firm, trust, corporation or other entity or combination thereof.

 

    	Actinium-Consulting Agreement
	Page 7 of 9	 

     

    

 

Actinium
Pharmaceuticals, Inc.

Confidential

 

WHEREFORE,
the parties hereto place their hands and seals:

 

	Dragan
    Cicic	 	ACTINIUM
    PHARMACEUTICALS, INC.
	 	 	 	 
	/s/
    Dragan Cicic	 	By:	/s/
    Sandesh Seth

 

    	Actinium-Consulting Agreement
	Page 8 of 9	 

     

    

 

Actinium
Pharmaceuticals, Inc.

Confidential

 

SCHEDULE
1

 

SERVICES

 

1.
Assist Company in understanding, analyzing and upgrading Actimab-A database

 

2.
Assist with all business development activity as needed

 

3.
Effectively transition projects set forth below to Company Dessignee

 

a.
antiCD38-Ac225 preclinical program

b.
venetoclax in combination with Actimab-A preclinical program

c.
Astellas Fab fragments Ac225 labeling and preclinical development program

d.
Actimab-A MDS expansion program

e.
Actimab-A in transplant program

f.
Iomab-B in combination with CAR-T program

g.
Other as applicable

 

4.
Advise the Company on matters regarding clinical and preclinical development, such as experimental pathways, clinical trial designs,
modifications in clinical trials etc.

 

5.
Provide medical and scientific input in regard to any regulatory questions arising and advise on regulatory strategies in that
respect

 

6.
Advise the Company on certain manufacturing and quality control issues related primarily to their potential implications regarding
safety and efficacy of Company’s drug candidates for both preclinical and clinical programs

 

7.
Provide written reports as requested by the Company based on the data provided from preclinical experiments and clinical trials

 

8.
Provide presentations on all of the above if requested

 

9.
Review reports and presentations on the above matters prepared by the Company and provide inputs on the same

 

10.
If requested, deliver presentations on the above matters to scientists, potential and actual investors and/or other appropriate
audiences

 

11.
Liaise with relevant scientists and other opinion leaders on behalf of the Company, if requested, to enable and/or facilitate
their collaboration with the Company

 

12.
Assist the Company in discussions with potential and/or actual development partners on both preclinical and clinical programs

 

13.
Assist Company in preparing and filing patent applications related to all of the above

 

14.
Make appropriate introductions to outside parties to enable successful transition and provide comprehensive list of contacts with
contact information related to above projects

 

 

	Actinium-Consulting Agreement
	Page 9 of 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}]]